Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors

Journal of Diabetes Investigation

Volumn 7, Issue 2, 2016, Pages 135-138

  Ogawa, Wataru ^a   Sakaguchi, Kazuhiko ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETIC KETOACIDOSIS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM;

BLOOD GLUCOSE; DIABETIC KETOACIDOSIS; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC NETWORKS AND PATHWAYS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84959366596     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12401     Document Type: Article

References (5)

1. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015. doi:10.2337/dc15-0843.
2. Hine J, Paterson H, Abrol E, et al. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 2015; 3: 503-504.
3. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 2015; 6: 587-590.
4. Kibbey RG. SGLT-2 inhibition and glucagon: cause for alarm? Trends Endocrinol Metab 2015; 26: 337-338.
5. Møller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care 2014; 37: 796-804.